Kolon resumes Invossa phase 3 clinical trials in US

After an ingredient mislabeling scandal, Kolon has won approval to continue phase 2 and 3 studies on the drug's different targets

Invossa, a cell and gene therapy for osteoarthritis
Invossa, a cell and gene therapy for osteoarthritis
Ju-Hyun Lee 1
2021-12-28 19:47:21 deep@hankyung.com
Pharmeceuticals

Kolon TissueGene Inc., the cell therapies unit of South Korean pharmaceutical company Kolon Life Science Inc., said on Dec. 28 it has resumed administering Invossa (TissueGene-C), a cell and gene therapy for osteoarthritis, for knee osteoarthritis in phase 3 clinical trials in the US. The clinical trials will be conducted in about 80 medical institutions for 1,020 patients. The Korean pharmaceutical company will complete the testing administration by 2023. 

The Ministry of Food and Drug Safety (MFDS) of Korea approved the drug in July 2017 as a cell and gene therapy for patients with degenerative joint disease. However, the health authorities canceled the drug licensing in March 2019, following a scandal that Kolon had manufactured the drug with a main ingredient different from that labeled at the time of approval.

According to the MFDS, the drug was labeled as using cartilage-derived cells, but it was actually using kidney-derived cells. In May 2019, the US Food and Drug Administration suspended the drug’s phase 3 clinical trials.

Kolon Life Science appealed to suspend the execution of MFDS’ order to stop manufacturing Invossa, however, the Seoul Central District Court dismissed the appeal in February of this year. 

In April 2020, FDA allowed Kolon TissueGene to resume clinical trials of Invossa after reviewing supplementary data from the Korean firm, including an explanation of how the drug composition has changed and additional data on the cell ingredients. Earlier this month, FDA approved Invossa’s phase 2 clinical trial for hip joint osteoarthritis, for the drug’s target expansion. 

“We expect a positive result from the phase 3 clinical trials as the scientific data from phase 1 and 2 clinical trials have high reliability and validity. By completing the clinical study successfully, we will make Invossa a game-changer in the global osteoarthritis therapy market,” said Kolon TissueGene Chief Executive Sung Han.

Write to Ju-Hyun Lee at deep@hankyung.com
Jihyun Kim edited this article.
#biotech #Kolon #Tissuegene #Invossa #pharma #genetherapy

SK Bioscience to sell Novavax COVID-19 vaccine in Thailand, Vietnam

SK Bioscience to sell Novavax COVID-19 vaccine in Thailand, Vietnam

Novavax's COVID-19 vaccine SK Bioscience Co., a biopharmaceutical unit of South Korea’s SK Group, said on Friday it has acquired non-exclusive rights to sell US-based Novavax Inc.’s COVID-19 vaccine to the governments of Thailand and Vietnam.The deal is part of an agreement between

SK Biopharm releases epilepsy treatment in UK

SK Biopharm releases epilepsy treatment in UK

SK Biopharm's Cenobamate, sold under the Xcopri brand in the US South Korean SK Biopharmaceuticals Co. launched its epilepsy treatment Cenobamate in the UK, rapidly expanding the company’s presence in Europe.The UK is the fourth country in Europe for SK to sell the drug, which is availabl

Activist fund again urges SK Chem to sell SK Bioscience stake

Activist fund again urges SK Chem to sell SK Bioscience stake

An SK Bioscience researcher tests medicine as part of vaccine development An activist fund has again urged South Korea’s SK Chemicals to sell part of its stake in SK Bioscience or buy back treasury shares and cancel them, saying the vaccine maker’s corporate value has not been fully

Korea approves export of Samsung Biologics-made Moderna vaccine

Korea approves export of Samsung Biologics-made Moderna vaccine

Samsung Biologics drug product manufacturing process (Courtesy of Samsung Biologics) South Korea approved exports of Moderna Inc.’s COVID-19 vaccine produced by Samsung Biologics Co. in a move that will help the country’s largest conglomerate Samsung Group accelerate the development

Samsung Biologics wins another Eli Lilly COVID treatment order

Samsung Biologics wins another Eli Lilly COVID treatment order

Samsung Biologics headquarters in Songdo, Incheon Samsung Biologics Co., a global contract development and manufacturing organization (CDMO), has stepped up its partnerships with global big pharmas by extending contracts and winning increased orders.The South Korean drugmaker signed a contract

Once high-flying bio stock hit by financial scandal

Once high-flying bio stock hit by financial scandal

Helixmith Co., once No.2 stock on the junior Kosdaq market, has lost 40% in the past week following its disclosure of $233 million investment in high-risk assets over the past few years. Its financial investment included an undisclosed amount injected into a domestic private equity fund that has sus
(* comment hide *}